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High Grade Vesicoureteral Reflux in ChildrenMarco Zaffanello
Department of Mother-Child and Biology-Genetics, University of Verona, Verona, Italy
Vesicoureteric reflux (VUR) occurs when there is ret-
rograde passing of urine back up the ureter. Urinary tract
infections (UTIs) have been considered the main cause of
permanent renal parenchymal damage in children with VU
reflux. Until now, management of this condition in chil-
dren has been directed at preventing UTIs by antibiotic
prophylaxis and/or surgical correction of VUR. Therefore,
Pennesi et al. reported in a recent multicenter, open label,
randomized controlled trial the ineffectiveness of antibi-
otic prophylaxis in avoiding new renal scars in children
with grade II/IV VUR. During a follow-up of four years,
antimicrobial prophylaxis was unable to reduce the risk of
recurring pyelonephritis and new renal scars in children
compared to untreated controls.[1] However, one of our
observational studies reported that surgical intervention
and pharmaceutical approaches lead to similar renal out-
come, quelling suspicions that today’s available measures
to limit renal damage are insufficient. In particular, we
found that high-grade VUR was associated with kidneys
that were already undersized at birth controlling/avoiding
the UTIs. In addition, both early antimicrobial prophylaxis,
given after prenatal detection, and a surgical approach do
not seem to alter the renal outcome: refluxing kidneys
always seem to grow slower than non-refluxing ones.[2]
In agreement, it is uncertain whether the treatment of
children with VUR confers clinically important benefits.
From a recent metaanalysis, the additional benefit of
surgery over antibiotics alone was reported to be minimal
at best, as no concomitant reduction in risk of new or pro-
gressive renal damage was shown after 10 years.[3]
Studies published in the last years, and in particular
improvements in prenatal diagnosis, have focused attention
on the association between renal dysplasia and VUR as
cause of chronic renal failure.[4] On the basis of these
findings, it is necessary to set new guidelines for the treat-
ment of children with VUR, as emerging knowledge
agrees with the failure of antimicrobial prophylaxis in
preventing renal scars and recurrence of UTIs.[5]
However, updated clinical information agrees with the
suspicions that moderate to severe VUR may be associ-
ated with a prenatal renal programming, which leads to a
delay in kidney growth. Obviously, when the VUR is
monolateral, the contra-lateral kidney often undergoes an
adjunctive overgrowth in compensation, but when the
VUR involves both kidneys, the renal growth delay may
be mutual.
Renal dysplasia associated with grade IV/V of VUR
has its own natural progression independent of pyelone-
phritis recurrences. The incidence of renal failure has
been stable even in years of aggressive treatment
approach. Interestingly, microalbumin excretion rate in
children with high-grade of VUR (IV-V) was signifi-
cantly increased than those with low-grade VUR and
control. In children with high-grade of VUR, both
microalbuminuria and reduction of renal function may be
a possible consequence of retrograde urine flow, glomer-
ulosclerosis, and hyperfiltration.[4] Perhaps therapy with
ACE-inhibitors in patients affected by proteinuria and/or
hypertension could prevent the worsening of nephropathy.[6,7]
but no studies about this item are yet available. At the
present time, it is impossible to modify significantly the
history of patients with severe bilateral nephropathy
from VUR.
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